[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oncology\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oncology":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,86,0,25,[9,48,72,106,130,163,185,215,239,275,301,328,348,373,394,432,460,479,510,538,561,589,625,684,713],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100645314","promoting-response-to-immunotherapy-by-exercise-in-patients-with-advanced-renal-cell-carcinoma-100645314",false,"NCT07680556","Promoting Response to IMmunotherapy by Exercise in Patients With Advanced Renal Cell Carcinoma","PRIMER","Inclusion Criteria:\n\n* Age ≥18 years.\n* Diagnosed with advanced RCC with indication for standard-of-care dual ICI treatment.\n* Able and willing to give written informed consent.\n\nExclusion Criteria:\n\n* Life expectancy \\\u003C6 months.\n* Unable to perform basic activities of daily living such as walking.\n* Presence of cognitive impairment or severe emotional instability (e.g. schizophrenia, Alzheimer's disease, alcohol addiction), at the discretion of the investigator.\n* Presence of other disabling comorbidities that may interfere with the ability to perform physical exercise (e.g., heart failure, chronic obstructive pulmonary disease (COPD, GOLD stage 3 or 4), orthopaedic conditions, or neurological disorders such as hernia, paresis, amputation or active rheumatoid arthritis), at the discretion of the investigator.\n* Current participation in structured vigorous aerobic and\u002For resistance exercise ≥ 2 times per week at a level comparable to the intervention","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","The primary aim of this study is to evaluate the feasibility of a supervised high intensity interval training (HIIT) program during first-line dual immune checkpoint inhibitor (ICI) therapy (nivolumab plus ipilimumab) in patients with advanced renal cell carcinoma (RCC). The second aim is to generate preliminary data on the effects of exercise on the immune cell phenotype and function, gut microbiota composition, physical fitness, patient-reported outcomes and clinical outcomes.\n\nThis is a two-arm randomized controlled pilot trial in which 30 patients with advanced RCC scheduled to receive first-line nivolumab plus ipilimumab will be randomized in 1:1 ratio to an exercise intervention group or usual care group. The exercise intervention consists of two 60-minute supervised HIIT sessions per week, delivered by oncology-trained physiotherapists and one additional home-based moderate-intensity aerobic exercise sessions per week. The intervention starts with the first cycle of immunotherapy and continues for four treatment cycles. Participants in both groups will receive usual care and general exercise guidelines. Measurements include blood and stool sampling for microbiome and immune parameters analysis, physical fitness assessments, physical fitness monitoring, body composition measurements, and patient-reported outcomes related to quality of life, fatigue, depression, sleep and diet.",[27],"Oncology",[27,29,30,31,32,33,34],"Exercise","immunotherapy","Renal cell carcinoma","immune-related adverse events","randomized controlled trial","immune function","NOT_YET_RECRUITING","2026-06-25",{"date":38,"type":39},"2026-07-02","ACTUAL",{"date":41,"type":21},"2026-07-01",{"date":43,"type":21},"2028-09-01",{"name":45,"class":46},"Radboud University Medical Center","OTHER",2,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":47},"100642172","physical-exercise-during-the-cancer-care-pathway-100642172","NCT07652502","Physical Exercise During the Cancer Care Pathway","ECOLE","Inclusion Criteria:\n\n* Age ≥18 years\n* Oncological diagnosis\n* Ability to understand the language of the respective country of origin\n* Electronic informed consent\n\nExclusion Criteria:\n\n\\- Failure to accept the informed consent",{"count":56,"type":21},370,"OBSERVATIONAL","Background: Physical exercise is proven safe and effective in improving quality of life and reducing treatment-related side effects in oncology. However, patient adherence to international guidelines remains suboptimal. Investigating the knowledge, attitudes, and practices (KAP) regarding physical activity is crucial to identifying unmet educational needs and barriers.\n\nObjective: This multicenter, cross-sectional observational study (ECOLE project) aims to assess KAP levels concerning exercise among cancer patients and explore the correlations between KAP scores and sociodemographic or clinical variables.\n\nMethods: Over a 6-month period, an anonymous online survey (Microsoft Forms) will be administered to adult cancer patients (≥18 years old) at any disease or treatment stage. A minimum sample size of 370 participants is targeted. Statistical analyses will include Descriptive Statistics, Exploratory and Confirmatory Factor Analyses to validate KAP scales, and Multivariable Logistic Regression to identify predictors of adherence (≥150 minutes\u002Fweek) and perceived barriers or facilitators.\n\nExpected Results: The study will provide a comprehensive overview of physical activity perceptions and behaviors in oncology. These insights will support the design of targeted educational interventions and structured exercise programs, contributing to the development of a novel \"Exercise Oncology Specialist\" within supportive care teams.",[60,61,27,62],"Cancer, Treatment-Related","Cancer","Oncologic Disorders","2026-06-23",{"date":65,"type":39},"2026-06-26",{"date":67,"type":21},"2026-06-15",{"date":69,"type":21},"2027-10-30",{"name":71,"class":46},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":82,"conditions":83,"keywords":84,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100346464","new-biomarkers-in-pancreatic-cancer-using-expel-concept-100346464","NCT03791073","New Biomarkers in Pancreatic Cancer Using EXPEL Concept","Discovery of New Biomarkers in Pancreatic Cancer Using Novel Nondestructive OMICS Methodology","PANEXPEL","Inclusion Criteria:\n\n* Patient with pancreatic mass and suspicion of pancreatic ductal adenocarcinoma requiring endoscopic ultrasound with fine needle biopsy or surgery\n* Patient ≥18 years old\n* Patient naïve of any treatment of Pancreatic cancer\n\nExclusion Criteria:\n\n* Patient who reject the study protocol",{"count":81,"type":21},200,"The investigators recently engineered a novel biomarker discovery approach that is non-destructive and fully compatible with OMICS profiling as well as routine clinical procedures (5). The latter approach - termed EXPEL - mines the interstitial tissue fluid that is the richest source of soluble, undiluted and uncontaminated biomarkers. The method notably gives access to proteins, metabolites, RNA, DNA and exosomes, thus enabling holistic biomarker discovery. Owing to its non-destructive nature, EXPEL provides for the first time both clinicians and researchers with the opportunity to analyze identical material.\n\nThe investigators hypothesize that the conservation liquid used to collect cells and biopsy after endoscopic ultrasound for pancreatic biopsy could contain the tissue secretome and permit a comprehensive OMICS analysis of PDAC (all stages confounded) by using a \"modified EXPEL\" procedure. These are ideal conditions for EXPEL approach that will additionally to finding novel biomarkers also shed light on complex network of cancer cell-stroma interactions.",[27],[85,86,87,88,89,90,91,92,93,94],"Biomarker discovery","Pancreatic adenocarcinoma","Bioinformatics","pancreatic cancer","microenvironment","proteomics","transcriptomics","metabolomics","diagnosis","Prognosis","RECRUITING","2026-06-17",{"date":98,"type":39},"2026-06-18",{"date":100,"type":39},"2018-01-01",{"date":102,"type":21},"2027-11-01",{"name":104,"class":46},"University Hospital, Montpellier",1,{"id":107,"slug":108,"hasResults":12,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":105},"100643563","phase-3-olanzapine-in-the-prevention-and-treatment-of-anorexia-cachexia-syndrome-in-patients-receiving-neoadjuvantpreoperative-chemotherapy-100643563","NCT07633236","Olanzapine in the Prevention and Treatment of Anorexia-Cachexia Syndrome in Patients Receiving Neoadjuvant\u002FPreoperative Chemotherapy","Olanzapine in the Prevention and Treatment of Anorexia-Cachexia Syndrome in Patients With Localized and Locally Advanced Tumors Receiving Neoadjuvant\u002FPreoperative Chemotherapy","Inclusion Criteria:\n\n* Age ≥18 years\n* ECOG status 0-2\n* Localized\u002Flocally advanced ovarian or gastric cancer requiring neoadjuvant\u002Fpreoperative chemotherapy followed by surgery\n* Ability to consume food\u002Fmedications orally\n\nExclusion Criteria:\n\n* Olanzapine use (\\>4 days) for other indications at enrollment\n* Current use of antipsychotics\u002Fantidepressants\n* Systemic corticosteroid use (\\>7 days within the last 4 weeks)\n* History of psychiatric disorders",{"count":114,"type":21},100,[116],"PHASE3","The goal of this clinical trial is to learn if olanzapine works to prevent and treat anorexia-cachexia syndrome and appetite loss in cancer patients. The main questions it aims to answer are:\n\nIs prolonged low-dose olanzapine effective and save in:\n\n* Preventing\u002Ftreating weight loss due to anorexia.\n* Controlling nausea\u002Fvomiting.\n* Maintaining anticancer therapy dose intensity?\n\nDoes prolonged low-dose olanzapine improve quality of life in patients receiving neoadjuvant\u002Fpreoperative chemotherapy?\n\nParticipants will:\n\nTake prolonged low-dose olanzapine (2.5 mg\u002Fday) in treatment group or usual diet only in control group until surgical treatment Physical examination, anthropometric assessment, blood tests, quality of life, appetite and nutritional status assessment, abdominal CT, handgrip dynamometry before chemotherapy and after preoperative chemotherapy before surgery Physical examination, adverse events every visit Surgical complications within 30 days after surgery",[119,120,27],"Oncology Patients Receiving Chemotherapy","Cachexia-Anorexia Syndrome","2026-06-03",{"date":123,"type":39},"2026-06-08",{"date":125,"type":39},"2025-03-28",{"date":127,"type":21},"2027-05-31",{"name":129,"class":46},"Blokhin's Russian Cancer Research Center",{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":138,"sex":17,"minAge":18,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":141,"briefSummary":142,"conditions":143,"keywords":145,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":105},"100582839","leading-healthy-eating-and-activity-promotion-program-100582839","NCT06868524","Leading Healthy Eating and Activity Promotion Program","Leveraging Adaptation and Multilevel Implementation Strategies to Address Unique Health Promotion Challenges Among Cancer Survivors","LEAP","Inclusion Criteria:\n\n* Between the ages of 18 and 89\n* English speaking\n* Resident of Birmingham area or surrounding community\n* History of any type of cancer or the friend or family with of a cancer survivor\n\nExclusion Criteria:\n\n* Serious difficulty hearing\n* History of dementia or organic brain syndrome\n* On primary treatment for cancer\n* No other other medical, psychological, or social characteristic that would interfere with participation in evaluation",true,"89 Years",{"count":114,"type":21},[24],"The goal of the LEAP project is to improve the health and well-being of cancer survivors and their co-survivors living in persistent poverty areas by providing healthy behavior change support. This will be done by engaging the community in adapting beneficial approaches for promoting healthy diet and regular physical activity into a program for cancer survivors and co-survivors that is appropriate for the persistent poverty context and social determinants of health.",[144,61,27],"Cancer Survivor",[146,147,148,149,150,151,152,153],"cancer survivor","cancer","oncology","exercise","nutrition","diet","healthy lifestyle","behavior change","2026-05-14",{"date":156,"type":39},"2026-05-19",{"date":158,"type":39},"2025-10-30",{"date":160,"type":21},"2029-03-01",{"name":162,"class":46},"University of Alabama at Birmingham",{"id":164,"slug":165,"hasResults":12,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":105},"100638437","chemokeyp-a-feasibility-study-for-realtime-safety-data-capture-for-potential-serious-adverse-drug-events-100638437","NCT07592234","Chemokeyp: A Feasibility Study for Realtime Safety Data-Capture for Potential Serious Adverse Drug Events","Chemokeyp: A Feasibility Study to Evaluate and Further Develop Patient Safety Software Enabling Efficient and Effective Information Exchange for Patients Undergoing Systemic Cancer Treatment Who Access Emergency or Unscheduled Care.","Inclusion Criteria:\n\n* Patient undergoing treatment for cancer at SVUH\n\nExclusion Criteria:\n\n* Presence of a condition(s) or diagnosis, either physical or psychological, or physical exam finding that precludes participation (inability to give informed consent)",{"count":114,"type":21},"Chemokeyp is a feasibility study testing a secure ED-Oncology interface for patients receiving chemotherapy who may present to unscheduled care with possible treatment-related complications.\n\nParticipants are enrolled through Oncology and issued a medical-alert-style wristband with a QR code. If they attend the Emergency Department, staff can scan the QR code, access a generic study landing page, and, after SVUH authentication, complete a short structured checklist about possible serious adverse events such as infection, chest pain, vomiting, syncope, or other red-flag symptoms.\n\nThe platform is designed as a secure research data-capture portal, not an electronic health record or clinical documentation system. It does not read from or write to the hospital EHR, does not provide clinical decision support, and does not change usual clinical care. Data entered by ED clinicians are limited to predefined structured fields for research and safety-signal feasibility purposes.\n\nThe study will assess whether ED clinicians can complete the checklist in real time, whether the information can support earlier notification to the research\u002Ftrial team, and whether this data accurately corresponds with verified serious adverse events. If feasible, Chemokeyp could help improve communication between Oncology, Emergency Medicine, and trial teams, supporting safer care for patients on chemotherapy and informing future development of ED-oncology digital safety tools.",[173,174,175,27],"Serious Adverse Events","Patient Safety","Pharmacovigilance","2026-05-11",{"date":178,"type":39},"2026-05-18",{"date":180,"type":39},"2026-02-01",{"date":182,"type":21},"2027-01-01",{"name":184,"class":46},"St Vincent's University Hospital, Ireland",{"id":186,"slug":187,"hasResults":12,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":193,"targetDuration":195,"studyType":57,"phases":4,"briefSummary":196,"conditions":197,"keywords":201,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":105},"100532920","nutritional-status-and-clinical-outcomes-in-patients-with-common-malignanciesncom-100532920","NCT06219083","Nutritional Status and Clinical Outcomes in Patients With Common Malignancies(NCOM)","Study of Nutritional Status and Clinical Outcomes in Patients With Common Malignancies","NCOM","Inclusion Criteria:\n\n* Adults aged 18 years and above\n* Pathologically diagnosed with malignant tumors\n* Scheduled to undergo radiotherapy and\u002For chemotherapy\n* Clear consciousness, no communication barriers\n* Willing to undergo follow-up, not in a near-death condition\n\nExclusion Criteria:\n\n* Patients without a pathological diagnosis of malignant tumors\n* Patients with AIDS\n* Patients with mental or cognitive disorders\n* Patients who have undergone organ transplantation\n* Patients with a life expectancy less than 12 months\n* Pregnant women\n* Patients currently participating in other clinical intervention studies",{"count":194,"type":21},1538,"5 Years","This multicenter, prospective cohort study investigates the long-term impact of nutritional status on clinical outcomes in cancer patients undergoing treatment in Shaanxi Province, China. It evaluates how malnutrition, dietary patterns, and nutritional interventions affect treatment tolerance, quality of life, and survival. The study tracks dynamic changes in nutritional health and related indicators throughout various stages of chemoradiotherapy, aiming to inform evidence-based strategies for precision nutrition in oncology care.",[61,198,199,27,200],"Chemoradiotherapy","Nutrition, Healthy","Clinical Outcomes",[198,202,203,204,205],"Nutritional Status in Cancer Patients","Clinical Outcomes of Cancer Treatment","Cancer Patient Nutrition","Shaanxi Province Cancer Study","2026-05-10",{"date":208,"type":39},"2026-05-12",{"date":210,"type":39},"2020-11-12",{"date":212,"type":21},"2031-12-01",{"name":214,"class":46},"Xiaoqin Luo",{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":223,"enrollmentInfo":224,"targetDuration":4,"studyType":22,"phases":226,"briefSummary":227,"conditions":228,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":47},"100578732","a-novel-ureteric-stent-in-kidney-stone-patients-and-oncology-patients-compared-to-a-conventional-jj-stent-100578732","NCT06815120","A Novel Ureteric Stent in Kidney Stone Patients and Oncology Patients Compared to a Conventional JJ Stent","Two Single Arm, Multicentre Unblinded First-in-human Trials Investigating a Novel Ureteric Stent to Determine the Reduction of Encrustation, Biofilm Deposition and Complications Compared to a Conventional JJ Stent","CASSETTE","Inclusion Criteria:\n\n1. Aged 18 years or over\n2. Ureteric stents clinically indicated either due to kidney stones or abdominal\u002Fpelvic cancers compressing ureters\n3. Previous experience with ureteric stents\n4. Awaiting insersion\u002Freplacement of stents\n5. Ability to give consent\n6. Ability to interact with study documentation\n7. Sufficient English to complete study documentations and questionnaires\n\nExclusion Criteria:\n\n1. Expected survival \\\u003C4months\n2. Unfit for stent insertion\n3. Unable to comply with study processes Pregnancy","99 Years",{"count":225,"type":21},50,[24],"Urological stents and catheters often lead to inflammation, causing pain and infection in the urinary tract. Moreover, 80% of stents are associated with pain, negatively impacting on QoL and mental health. Offering novel designs with significantly lower E\\&B leads to a reduction in UTIs and improves QoL. Reducing hospital admissions (from 3 to 1 per patient, annually) would free \\>100,000 bed-nights, allowing the elderly to regain independence. Our proposed research could have a significant impact towards fulfilling the 'healthy-ageing' Grand Challenge. Additionally, the novel stent reduces prevalence of infections and therefore, of antibiotic prescriptions contributing to the Global AMR challenge.",[229,27,230],"Catheter Blockage","Kidney Stone","2026-05-06",{"date":176,"type":39},{"date":234,"type":39},"2025-08-06",{"date":236,"type":21},"2026-12-31",{"name":238,"class":46},"University of Southampton",{"id":240,"slug":241,"hasResults":12,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":223,"enrollmentInfo":247,"targetDuration":4,"studyType":22,"phases":249,"briefSummary":250,"conditions":251,"keywords":257,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":105},"100577247","the-implementation-of-the-go-wish-game-to-promote-advance-care-planning-in-onco--hematologic-disease-100577247","NCT06795815","The Implementation of the Go Wish Game to Promote Advance Care Planning in Onco- Hematologic Disease","The Implementation of the Go Wish Game to Promote Advance Care Planning in Onco-hematologic Disease (Onco-hema Go Wish-ACP): Intervention Set up and Multicentre Feasibility Trial","OHGW-ACP","Inclusion Criteria:\n\n* ≥ 18 years age; diagnosed with refractory lymphomas, or leukemia or multiple myeloma or advanced solid tumors and estimated prognosis \\> 3 months;\n* able to communicate in Italian and\n* to give written consent to the study.\n\nExclusion Criteria:\n\n* Patients with severe cognitive impairment or serious psychiatric condition;\n* refusal to participate to the study",{"count":248,"type":21},75,[24],"This is a mixed-method, device-free and drug-free multicenter interventional study. The study aims at facilitating end-of-life conversations within the doctor-patient relationship through the use of the Go Wish Game (GWG) and supporting patients, their caregivers and healthcare professionals to complete Advance Care Panning documentation.\n\nThe GWG helps people clarify and identify their priorities, should they be affected by a chronic, disabling and potentially non-healing illness. In fact, the GWG consists of a small deck of cards, and on each card is a concrete action or situation that may be important to a person at the end of life.\n\nThe \"Onco-hema Go wish-ACP\" project aims to evaluate the feasibility of a Go Wish Game-based intervention with patients with refractory lymphoma, leukemia or multiple myeloma or advanced solid tumors with prognosis \\> 3 months.\n\nIn terms of secondary objectives, the study aims to.\n\n* Evaluate and compare the intervention with hematology and oncology patients in terms of: - Other feasibility indicators; Involvement in CCP pathways; Quality of communication; Meaning of life; Impact on hope; through a series of questionnaires administered to patients and caregivers involved in the intervention\n* Qualitatively assess the acceptability of the intervention in terms of recruitment and delivery with patients and caregivers through semi-structured interviews and with professionals through Focus Groups (FGs).\n* To analyze the clinical records of enrolled patients in terms of: values and preferences; awareness of prognosis; end-of-life choices and shared decision-making on treatment decisions.",[252,253,254,255,27,256],"Leukemia","Multiple Mieloma","Advanced Solid Tumors","Lymphoma","Hematologic Diseases",[258,259,260,261,27,262,263,264],"Advance Care Planning","Go Wish Game","Medical Oncology","Hematology","Palliative Care","Experimental Design Study","Mixed Methods","2026-05-04",{"date":267,"type":39},"2026-05-07",{"date":269,"type":39},"2025-06-30",{"date":271,"type":21},"2026-07",{"name":273,"class":274},"Azienda USL Reggio Emilia - IRCCS","OTHER_GOV",{"id":276,"slug":277,"hasResults":12,"nctId":278,"briefTitle":279,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":281,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":283,"conditions":284,"keywords":285,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":297,"leadSponsor":299,"locationsCount":105},"100633853","implementing-ai-assisted-patient-friendly-imaging-report-summaries-to-enhance-oncology-care-delivery-100633853","NCT07532083","Implementing AI-Assisted, Patient-Friendly Imaging Report Summaries to Enhance Oncology Care Delivery","Inclusion Criteria (Patient Participants):\n\n* Age 18 years or older\n* Having a current or prior cancer diagnosis (any cancer type)\n* Has active access to the UW Health MyChart patient portal.\n* Receiving care at UW Health within the Division of Hematology, Medical Oncology and Palliative Care or Department of Gynecologic Oncology.\n* Undergoing imaging studies (such as CT, MRI, or PET scans) as part of routine cancer care.\n* Willing and able to complete electronic REDCap surveys.\n* For interview participation: willing to participate in a 30-45-minute phone or video interview.\n\nInclusion Criteria (Provider Participants): Cancer care providers will be eligible to participate in this study if they meet all of the following criteria:\n\n* Faculty physician (MD or DO) practicing in the Division of Hematology, Medical Oncology and Palliative Care or Department of Gynecologic Oncology at UW Health.\n* Involved in reviewing, discussing, or sharing imaging results with patients.\n* Planned to gain access to the AI-assisted, patient-friendly imaging summary tool as part of clinical implementation.\n* Willing and able to complete electronic surveys or participate in a brief interview (\\~30 minutes).\n\nExclusion Criteria (Patients):\n\n* Are unable to provide informed consent due to cognitive impairment or other limitations, as determined by the clinical or study team.\n* Enrolled in an active interventional clinical trial. Patients on biospecimen, registry, or non-interventional studies are eligible.\n* For the Patient Interview group only: Patients with radiographic disease progression will be excluded.",{"count":282,"type":21},2000,"The implementation of the AI-assisted radiology summary tool into clinical workflows is being conducted as part of a standard-of-care quality improvement (QI) initiative at UW Health. The evaluation of this tool's impact via structured feedback from patients and providers is being undertaken as a prospective research study.",[27],[286,287,288,289,290,291,292],"Patient Care","Patient Communication","AI","Artificial Intelligence","Radiology","Imaging","Summary Reports","2026-04-28",{"date":295,"type":39},"2026-04-30",{"date":180,"type":39},{"date":298,"type":21},"2027-01",{"name":300,"class":46},"University of Wisconsin, Madison",{"id":302,"slug":303,"hasResults":12,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":138,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":22,"phases":311,"briefSummary":312,"conditions":313,"keywords":315,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":105},"100612017","effectiveness-of-the-mindful-compassion-care-program-for-healthcare-professionals-in-oncology-and-palliative-care-100612017","NCT07248111","Effectiveness of the Mindful Compassion Care Program for Healthcare Professionals in Oncology and Palliative Care","Effectiveness of the Mindful Compassion Care Program for Healthcare Professionals in Oncology and Palliative Care: a Randomized Controlled Trial With a Qualitative Component","MCCP","Inclusion Criteria:\n\n* Being a healthcare professional (physicians, nurses, or nursing assistants) involved in the clinical management of cancer patients across different care settings and illness phases.\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* HPs must not have attended MBSR or other mindfulness\u002Fcompassion-based interventions, including in educational or clinical settings, involving activities similar to those in the present study in the previous six months.",{"count":310,"type":21},160,[24],"This randomized controlled trial aims to evaluate the effectiveness of the Mindful Compassion Care Program (MCCP), a mindfulness- and compassion-based intervention designed to enhance the emotional and professional well-being of healthcare professionals (HPs). The study adopts a multi-center, open-label, randomized, parallel-group, superiority design and includes HPs (physicians, nurses, and nursing assistants) involved in the clinical care of cancer patients across different settings and disease phases. Eligible participants must not have attended MBSR or other mindfulness-\u002Fcompassion-based interventions in the preceding six months.\n\nThe RCT has a primary objective of assessing the MCCP's effectiveness in increasing positive emotions and reducing negative emotions among HPs working in oncology and palliative care. Secondary objectives include evaluating improvements in professional quality of life and self-compassion. After providing informed consent, HPs will be randomized to receive either the MCCP (experimental group) or no intervention (control group).",[314,262,27],"Professional Quality of Life",[316,317,318,319,320],"mindfulness","self-compassion","emotional regulation","supportive care","mental health promotion",{"date":322,"type":39},"2026-04-29",{"date":324,"type":21},"2027-12",{"date":326,"type":21},"2028-01",{"name":273,"class":274},{"id":329,"slug":330,"hasResults":12,"nctId":331,"briefTitle":332,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":334,"targetDuration":4,"studyType":22,"phases":335,"briefSummary":336,"conditions":337,"keywords":339,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":346,"locationsCount":47},"100605699","effects-of-a-group-versus-individual-cognitive-training-program-on-chemotherapy-induced-cognitive-impairment-chemobrain-in-breast-cancer-patients-undergoing-active-treatment-100605699","NCT07165912","Effects of a Group Versus Individual Cognitive Training Program on Chemotherapy-induced Cognitive Impairment (Chemobrain) in Breast Cancer Patients Undergoing Active Treatment","Inclusion Criteria:\n\nBeing an adult (18 years or older). Having a recent histopathological diagnosis of newly diagnosed breast cancer and starting oncological treatment.\n\nBeing fully capable of performing daily functions. Willingness to voluntarily participate in the study and signing the informed consent.\n\nExclusion Criteria:\n\nLack of literacy skills or significant language comprehension deficit. Diagnosis of a Central Nervous System tumor or participation in another cognitive stimulation program.\n\nClinical diagnosis of a neurocognitive disorder as defined in the DSM-V.\n\nWithdrawal Criteria:\n\nDropping out of the program or not completing the final evaluation",{"count":248,"type":21},[24],"Introduction: The significant improvement in breast cancer survival, largely attributable to biomedical and technological progress, makes it increasingly necessary to investigate the secondary effects linked to this pathology. Among these, cancer-related cognitive impairment (CRCI) stands out as one of the most frequent yet frequently overlooked complications.\n\nObjective: To evaluate the impact of a structured cognitive training program on the management of CRCI in patients with breast cancer receiving active treatment.\n\nMethodology: A randomized controlled clinical trial will be conducted with two arms: an Intervention Group (IG) and a Control Group (CG). The study will include patients with a recent diagnosis of breast cancer. Based on sample size calculations, 50 participants will be recruited-25 per group-to detect a minimum difference of 2.95 points on the MoCA (Montreal Cognitive Assessment), a tool commonly used to assess cognitive performance. All participants will receive an informational leaflet aligned with the latest WHO recommendations for preventing cognitive decline. In addition, the IG will complete an individualized cognitive training (CT) program focused on everyday cognitive skills (EC). The program will provide a dossier with 80 training sessions, structured into four phases (P1-P4) of 20 activities each, to be implemented monthly. Baseline assessments and a follow-up four months after the intervention will be carried out in both groups. Variables collected will include sociodemographic and clinical data, as well as outcome measures for cognitive status (MoCA), everyday cognition (PECC), anxiety levels (Hamilton scale), functional capacity (LB), sleep quality (PSQI), quality of life (ECOG), and subjective memory complaints (FACT-COG).\n\nImpact: Findings from this study could support the development of targeted cognitive rehabilitation strategies and the implementation of clinical protocols for individuals undergoing breast cancer treatment. By addressing CRCI-an underrecognized but increasingly prevalent issue given rising survival rates-these interventions may contribute to improving patients' overall quality of life.",[338,27],"Breast Cancer Females",[340,61],"Cognitive training","2026-04-27",{"date":293,"type":39},{"date":344,"type":21},"2026-05-01",{"date":236,"type":21},{"name":347,"class":46},"University of Salamanca",{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":354,"eligibilityCriteria":355,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":356,"targetDuration":4,"studyType":22,"phases":358,"briefSummary":359,"conditions":360,"keywords":363,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":366,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":105},"100542739","feasibility-and-acceptability-of-internet-based-parent-child-interaction-therapy-i-pcit-in-pediatric-cancer-100542739","NCT06346782","Feasibility and Acceptability of Internet-based Parent-child Interaction Therapy (I-PCIT) in Pediatric Cancer","Feasibility, Acceptability, and Preliminary Efficacy of an Internet-based Parent-child Interaction Therapy (I-PCIT) Intervention for Children With Cancer","I-PCIT","Inclusion Criteria:\n\n* Participants will be parents of 2-12 year-old children who (1) currently or previously received cancer treatment and\u002For long-term cancer follow-up care at Johns Hopkins All Children's Hospital (JHACH).\n* The child's cancer treatment must have included or plan to include chemotherapy and\u002For radiation.\n* The child's cancer diagnosis must have been conferred at least 6 weeks prior to study enrollment. If a patient's cancer relapses during the study period, the patient's oncologist must agree to the patient continuing in this intervention.\n* The parent must have access to reliable internet service (e.g., in their own home, in a friend or family member's home, via cell phone carrier) and their own smartphone, tablet, or computer to participate in telehealth intervention sessions.\n\nExclusion Criteria:\n\n* Parents will be excluded if they or their child have cognitive, motor, or language delays that would preclude participation, as observed by research staff or listed in the child's medical record. Hearing impaired parents will also be excluded because I-PCIT requires the coach to verbally coach parents via bug-in-ear.\n* Parents will be excluded if their child is expected to undergo bone marrow transplant (BMT) during the study or has received BMT within 2 months of study enrollment.\n* The child must not be receiving end of life care, as determined by medical chart review and\u002For consultation with the patient's medical team.",{"count":357,"type":21},300,[24],"This study is being done to learn whether a telehealth intervention called \"Internet-Based Parent Child Interaction Therapy,\" or I-PCIT,\" can help parents improve the child's behavior if the child currently or previously went through cancer treatment.\n\nParents who choose to be in this study will complete a survey to help researchers figure out if the parent is eligible for the larger study. If a parent is eligible for the larger study and chooses to participate, if so, the participants will be randomly assigned to either receive the I-PCIT intervention now or to be on a waitlist and begin I-PCIT in 5-6 months. The whole study consists of completing I-PCIT sessions with a clinician and completing 3-4 follow-up surveys after the initial screener survey.",[361,27,362],"Pediatric Cancer","Disruptive Behavior",[361,27,364,365,362],"Parent","Parenting",{"date":295,"type":39},{"date":368,"type":39},"2024-02-19",{"date":370,"type":21},"2028-08-01",{"name":372,"class":46},"Johns Hopkins All Children's Hospital",{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":379,"eligibilityCriteria":380,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":22,"phases":383,"briefSummary":384,"conditions":385,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":105},"100627286","step2-vs-routine-early-palliative-care-randomized-noninferiority-trial-100627286","NCT07446660","STEP2 vs. Routine Early Palliative Care: Randomized Noninferiority Trial","Symptom Screening With Targeted Early Palliative Care (STEP2) Versus Routine Early Palliative Care in Patients With Advanced Cancer: A Randomized Noninferiority Trial","STEP2 RNT","Inclusion Criteria:\n\n* Age ≥18 years\n* Stage IV cancer (endocrine-resistant ER+ breast and castration-resistant prostate cancer; stage 3 included for lung or pancreatic cancer)\n* Oncologist-estimated Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Oncologist-estimated prognosis of 6-36 months\n* Willingness to complete virtual ESAS-r+ screening before each appointment\n\nExclusion Criteria:\n\n* Insufficient English literacy to complete study questionnaires\n* Severe cognitive deficit, as per treating oncologist\n* Receiving specialized palliative care",{"count":382,"type":21},652,[24],"Palliative care aims to improve quality of life for people with advanced illness, and early palliative care (EPC) has been shown to benefit patients with late-stage cancer. However, specialist teams do not have the capacity to see all patients; on the other hand, many who would benefit are not referred. To address this, the investigators created STEP2, a system that combines online symptom screening with targeted palliative referrals. Eligible patients with advanced cancer are randomly assigned to routine EPC-where all receive a referral-or to STEP2, where referrals occur only if moderate-to-severe symptoms are reported. Patients complete questionnaires on quality of life, satisfaction, symptoms, depression, and goals of care at baseline, 16 weeks, and 24 weeks. The study will assess whether STEP2 is as good as receiving routine EPC by comparing the results of the questionnaires in each group.",[27],"2026-04-22",{"date":293,"type":39},{"date":389,"type":39},"2026-03-23",{"date":391,"type":21},"2030-07",{"name":393,"class":46},"University Health Network, Toronto",{"id":395,"slug":396,"hasResults":12,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":400,"eligibilityCriteria":401,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":402,"targetDuration":4,"studyType":22,"phases":404,"briefSummary":406,"conditions":407,"keywords":416,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":431},"100541173","phase-1-a-study-to-investigate-the-safety-and-efficacy-of-nst-628-oral-tablets-in-subjects-with-solid-tumors-100541173","NCT06326411","A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors","A Phase I, Open Label Single-arm Two-part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy of Pan-RAF\u002FMEK Glue NST-628 Oral Tablets in Subject With Solid Tumors Harboring Genetic Alterations in the MAPK Pathway and With Other Solid Tumors","NST-628","Inclusion Criteria:\n\nSubjects are eligible to be included in the study only if all of the following criteria apply:\n\n1. Subjects must be ≥18 years old (or of legal age of consent in the country in which the study is taking place) at the time of signing the informed consent.\n2. Subjects who have a histologically or cytologically documented metastatic or locally advanced solid tumor, for which standard of care (SoC) therapy does not exist, no longer provides benefit, or is not tolerated by the subject, or the subject has been assessed by the Investigator as not being suitable for SoC therapy.\n\n   1. Part A: Subjects with any solid tumor with genetic alteration of or evidence of tumor dependence upon the RAS\u002FMAPK pathway (subject to additional restrictions specified in the study protocol)\n   2. Part B: Subjects must be diagnosed with one of the following solid tumors harboring specified genetic alterations based on a validated local test:\n\n   i. Melanoma Cohorts:\n   1. Activating NRAS mutations\n   2. Select BRAF alterations\n\n   ii. Non-Melanoma Cohorts:\n   1. Solid tumors with NRAS activating mutations\n   2. Solid tumors with KRAS activating mutations\n   3. Solid tumors with select BRAF alterations\n   4. Glioma with BRAF alterations\n3. Newly obtained or archived tumor tissue is required\n4. Part B: measurable disease as defined by RECIST Version 1.1 or by other disease assessment tool standard for a given tumor type (if RECIST v. 1.1 is not standard)\n5. Performance status\n\n   1. Solid tumors other than glioma: ECOG 0 or 1\n   2. Glioma: Karnofsky ≥ 70 and ECOG 0 or 1\n6. Have adequate organ function\n7. Understand and voluntarily sign an Institutional Review Board\u002FIndependent Ethics Committee-approved informed consent form prior to any study-specific evaluation.\n8. Life expectancy ≥ 12 weeks\n\nExclusion Criteria:\n\nSubjects are excluded from the study if any of the following criteria apply:\n\n1. Conditions interfering with oral intake of NST-628\n2. Conditions interfering with intestinal absorption of an orally administered drug\n3. A history or current evidence of significant retinal pathology leading to increased risk of RVO\n4. A history or evidence of cardiovascular risk\n5. Current or history within 6 months of planned Cycle 1 Day 1 of pneumonitis or interstitial lung disease (ILD)\n6. Part B: prior treatment with any MEK or BRAF inhibitor\n7. Untreated or symptomatic central nervous system (CNS) metastases\n8. Chemotherapy, radiation, gene therapy, vaccine therapy, or anti-cancer antibodies \u002F ADCs within 28 days of Cycle 1 Day 1\n9. Targeted small molecule agents within 14 days or 5 half-lives of Cycle 1 Day 1\n10. Females who are pregnant or breastfeeding.\n11. For fertile patients (female able to become pregnant or male able to father a child), refusal to use effective contraception during the period of the trial and for 6 months after the last dose of NST-628\n12. Presence of any serious or unstable concomitant systemic disorder incompatible with the clinical study",{"count":403,"type":21},230,[405],"PHASE1","This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated\u002Fdependent advanced solid tumors who have exhausted standard treatment options.",[27,408,409,410,411,412,413,414,415],"MEK Mutation","RAF Gene Mutation","Ras (KRAS or NRAS) Gene Mutation","Melanoma","NSCLC","Glioma","Solid Tumor, Adult","MAPK Pathway Gene Mutation",[417,418,419,420],"RAS","MEK","RAF","solid tumor","2026-04-15",{"date":423,"type":39},"2026-04-20",{"date":425,"type":39},"2024-04-09",{"date":427,"type":21},"2029-11",{"name":429,"class":430},"Nested Therapeutics, Inc","INDUSTRY",23,{"id":433,"slug":434,"hasResults":12,"nctId":435,"briefTitle":436,"officialTitle":436,"acronym":437,"eligibilityCriteria":438,"healthyVolunteers":12,"sex":17,"minAge":439,"maxAge":4,"enrollmentInfo":440,"targetDuration":4,"studyType":22,"phases":442,"briefSummary":443,"conditions":444,"keywords":446,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":450,"lastUpdatePostDateStruct":451,"startDateStruct":453,"completionDateStruct":455,"leadSponsor":457,"locationsCount":459},"100569696","a-decisional-intervention-for-older-adults-with-acute-myeloid-leukemia-and-their-caregivers-100569696","NCT06697600","A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers","UR-GOAL RCT","Patients\n\nInclusion criteria:\n\n* Age ≥60 years (from date of consent, confirmed on electronic medical records)\n* A new diagnosis of AML\n\n  * Diagnosis can be based on the International Consensus Classification or World Health Organization\n  * Myeloid sarcoma is allowed\n  * AML with central nervous system involvement is allowed\n* Cancer-directed treatment has not started\n\n  * Treatment to temporarily decrease white blood cells is acceptable; these may include hydroxyurea, leukapheresis, or cytarabine\n  * Intrathecal chemotherapy is acceptable\n* The patient's oncologist has been or will be enrolled on the study\n* English or Spanish-speaking\n* Patients without a caregiver will still be eligible to participate in the study Exclusion criteria\n* A diagnosis of acute promyelocytic leukemia\n* Patients with psychiatric or cognitive conditions which the treating oncologist believes prohibits informed consent or compliance with study procedures\n* Prior cancer-directed treatment for AML\n\nCaregivers\n\nInclusion criteria:\n\n* Selected by the patient when asked if there is a \"family member, partner, friend or caregiver \\[age 18 or older\\] with whom you discuss or who can be helpful in healthrelated matters.\"\n* Caregiver may be paid\u002Fprofessional or informal caregiver\n* Able to provide informed consent\n* English or Spanish-speaking\n\nOncologists\n\nInclusion criteria:\n\n• Oncologists caring for patients with AML Exclusion criteria","60 Years",{"count":441,"type":21},1020,[24],"This is a multicenter randomized controlled trial that assesses the efficacy of a decisional intervention \\[University of Rochester-Geriatric Oncology assessment for Acute myeloid Leukemia (UR-GOAL)\\] compared to an attention control.",[27,445,61],"Myeloid Leukemia, Acute",[447,448,449],"older adults","geriatric oncology","caregivers","2026-03-29",{"date":452,"type":39},"2026-03-31",{"date":454,"type":39},"2025-07-11",{"date":456,"type":21},"2030-06-01",{"name":458,"class":46},"University of Rochester",4,{"id":461,"slug":462,"hasResults":12,"nctId":463,"briefTitle":464,"officialTitle":464,"acronym":4,"eligibilityCriteria":465,"healthyVolunteers":138,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":466,"targetDuration":4,"studyType":22,"phases":467,"briefSummary":468,"conditions":469,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":450,"lastUpdatePostDateStruct":470,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":478},"100534360","ctnow-a-clinical-trials-education-program-for-rural-cancer-patients-and-oncology-providers-100534360","NCT06237816","CTNow: A Clinical Trials Education Program for Rural Cancer Patients and Oncology Providers","Inclusion Criteria:\n\n* Patients must have been diagnosed with any cancer.\n* Patients who have received treatment, are receiving cancer treatment at the time of enrollment, or estimated to start treatment within 90 days.\n* Patients must be ≥ 18 years of age. Patients must be able to read, write, and speak English. Study materials and telephone calls are only available in English.\n\nPatients must be residents of Hawaii, Kauai, or Maui counties.\n\nExclusion Criteria:\n\n* Patients must not have previously participated in a cancer clinical trial. Those who have participated in a cancer clinical trial are not eligible for the study.",{"count":225,"type":21},[24],"The overall goal of the project is to pilot test CTNow, a multilevel intervention designed to facilitate access and referrals to cancer clinical trials in rural areas through patient and provider education and teleconference resources.",[61,27],{"date":471,"type":39},"2026-04-03",{"date":473,"type":39},"2025-05-01",{"date":475,"type":21},"2026-12",{"name":477,"class":46},"University of Hawaii",3,{"id":480,"slug":481,"hasResults":12,"nctId":482,"briefTitle":483,"officialTitle":483,"acronym":484,"eligibilityCriteria":485,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":486,"targetDuration":4,"studyType":22,"phases":488,"briefSummary":489,"conditions":490,"keywords":496,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":500,"lastUpdatePostDateStruct":501,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":507,"locationsCount":509},"100581945","behavioral-and-adherence-model-for-improving-quality-health-outcomes-and-cost-effectiveness-of-healthcare-100581945","NCT06856902","BEhavioral and Adherence Model for Improving Quality, Health Outcomes and Cost-Effectiveness of healthcaRe","BEAMER","Inclusion Criteria:\n\n* Having the diagnosis of the pilot sites target groups described above as per clinical assessment or validated diagnosis criteria\n* Having the age of the pilot sites target groups described above\n* Having accepted to participate in the study and provided written informed consent\n* Having the availability to participate on all study activities\n\nExclusion Criteria:\n\n* Individuals that do not fulfil ALL the inclusion criteria will be excluded to participate.",{"count":487,"type":21},3100,[24],"Lack of adherence to treatment is a widespread issue worldwide, which leads to higher healthcare utilisation rates and even premature death. While the level of adherence may differ based on the specific condition and treatment, studies estimate that approximately 50% of medications are not taken according to the prescribed instructions. In addition, adherence rates tend to decrease even further when the treatment requires a behavioural change. Literature reviews about factors that affect people's adherence show that it is challenging to predict whom can be considered to have adherent and non-adherent behaviours. In addition, the studies highlight that it is challenging to support a person to be adherent. Based on this knowledge the BEAMER project was established (Behavioural and Adherence Model for improving quality, health outcomes and cost-Effectiveness of healthcaRe). The overall goal of the project is to improve the quality of life of individuals, enhance healthcare accessibility and sustainability, thereby transforming the way healthcare stakeholders engage with patients to understand their condition and adherence levels throughout their healthcare journey. To address the overall goal, the BEAMER project has developed a disease agnostic model named \"B-COMPASS: BEAMER-COmputational Model for Patient Adherence and Support Solutions\". The aim of the B-COMPASS is to identify patients' needs and preferences which enables the creation of patient-specific supports, with the intention of improving their adherence to treatment within the heterogeneity of the different disease-areas and healthcare contexts. Based on the validated BEAMER questionnaire, the B-COMPASS predicts relative adherence and offers an elicitation process of patient needs and preferences to enable targeted supports to improve patient adherence. This results in an allocation of patients to different groups based on their needs and preferences. Overall, the B-COMPASS provides patient insights that will enable more effective design of patient support, most likely resulting in better patient experience, improved adherence and lower healthcare and societal costs.\n\nSo far, several activities from a technical and user perspective have already been conducted in the project to refine the B-COMPASS. This has been done by applying an iterative mixed method approach were both stakeholders (regulator, pharma, academic\u002Fresearch and small and medium-sized enterprises) and end users (patients, health providers and health systems) have been involved. Despite the finetuning of the B-COMPASS, the effectiveness of the B-COMPASS hinges on empirical investigations into the structural elements that impact patient behaviour and the identification of predictive factors that can assist healthcare providers' (HCP) and Research Leads in designing more effective treatment plans (the term HCPs\u002FResearch Lead include both the individuals and the institutions where care is delivered). Therefore, validation studies will be conducted to assess the B-COMPASS's performance in six therapeutic areas (cardiovascular, endocrinology, immunology, neurology, oncology and rare diseases) with patients recruited in at least Italy (FISM), Portugal (APDP and MEDIDA) Norway (AHUS), Spain (FHUNJ and FIIBAP), The Netherlands (WDO), and Germany (UDUS). The collected data will be used to evaluate the B-COMPASS's capacity to attend to a variety of needs and challenges for adherence.",[491,492,493,494,27,495],"Cardiovascular Diseases","Endocrinology","Inmunology","Neurology","Rare Diseases",[497,498,499],"Digital health","adherence to treatment","healthcare","2026-03-26",{"date":502,"type":39},"2026-04-01",{"date":504,"type":39},"2025-03-01",{"date":506,"type":21},"2026-09-30",{"name":508,"class":46},"Technical University of Madrid",10,{"id":511,"slug":512,"hasResults":12,"nctId":513,"briefTitle":514,"officialTitle":515,"acronym":4,"eligibilityCriteria":516,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":517,"targetDuration":4,"studyType":22,"phases":519,"briefSummary":521,"conditions":522,"keywords":526,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":532,"completionDateStruct":534,"leadSponsor":536,"locationsCount":4},"100631713","phase-1-phase-12a-study-of-rp-001-in-participants-with-advanced-malignancies-100631713","NCT07504263","Phase 1\u002F2a Study of RP-001 in Participants With Advanced Malignancies","An Open-label, Multicenter, Phase 1\u002F2a Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of RP-001 in Participants With Advanced Malignancies","Inclusion Criteria:\n\n* Male or female participants aged 18 years or older with advanced or metastatic cancer, which must be measurable per RECIST v1.1 and satisfy the following criteria:\n\n  * Phase 1: Participants with solid tumors who are candidates for treatment with a taxane\n  * Phase 2a: Participants with relapsed or refractory PDAC, or CRC.\n\nExclusion Criteria:\n\n* 1\\. Active infection requiring systemic anti-infective therapy within 28 days prior to first dose of RP-001.\n\n  2\\. Cardiovascular disease, including:\n\n  a. Unstable angina; b. symptomatic peripheral arterial vascular disease; c. Myocardial infarction within 6 months prior to RP-001 administration; d. New York Heart Association Class III or IV heart failure; e. Uncontrolled arrythmia; f. ECG abnormality that, in the opinion of the Investigator, increases the risks associated with participating in the trial.\n\n  3\\. Concurrent systemic anti-cancer therapy other than luteinizing hormone-releasing hormone (LH-RH) agonists.\n\n  4\\. Pregnancy, or breastfeeding. 5. Untreated central nervous system metastasis, or carcinomatous meningitis. 6. Any concurrent severe and\u002For uncontrolled medical or surgical condition which, in the opinion of the Investigator, may compromise the participant's involvement in the trial due to safety, compliance concerns or ability to evaluate response.",{"count":518,"type":21},66,[405,520],"PHASE2","Phase 1\u002F2a Study of RP-001 in participants with Advanced Malignancies",[523,27,524,525,61],"Advanced Malignancies","Colorectal Cancer","Pancreatic Cancer",[527,528,529],"advanced malignancies","colorectal cancer","pancreatic ductal adenocarcinoma","2026-03-25",{"date":452,"type":39},{"date":533,"type":21},"2026-04-23",{"date":535,"type":21},"2028-04-01",{"name":537,"class":430},"Recurv Pharma Inc",{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":543,"acronym":544,"eligibilityCriteria":545,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":546,"targetDuration":4,"studyType":22,"phases":548,"briefSummary":550,"conditions":551,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":553,"startDateStruct":555,"completionDateStruct":557,"leadSponsor":559,"locationsCount":105},"100518491","phase-4-evaluating-the-safety-of-shortened-infusion-times-for-different-oncological-immunotherapie-100518491","NCT06031233","Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie","Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapies; An Observational Prospective Study","MINUTE","Inclusion Criteria:\n\n* Starting treatment with monoclonal antibodies: nivolumab, pembrolizumab ipilimumab, bevacizumab, trastuzumab, durvalumab or atezolizumab.\n* 18 years and older.\n* No known history of increased susceptibility to immunological reactions.\n* Subject is able and willing to sign the Informed Consent Form prior to screening evaluations.\n\nExclusion Criteria:\n\n* Other research medication within 4 weeks of the start of the study.\n* Inclusion in medical research in which the administration of medication should follow its stated times and dosages of infusions\n* Dosage deviates from standard protocol\n* Patients whom receive drugs through a central venous catheter (and for example porth-a-cath).",{"count":547,"type":21},776,[549],"PHASE4","This study is an interventional, explorative, prospective study to show whether shortening of infusion times for patients using nivolumab, pembrolizumab, ipilimumab, trastuzumab, bevacizumab, durvalumab or atezolizumab continues to be associated with an acceptable safety profile.\n\nInfusion times will be gradually shortened if tolerability allowes.",[27,552],"Infusion Reaction",{"date":554,"type":39},"2026-03-30",{"date":556,"type":39},"2023-09-01",{"date":558,"type":21},"2028-12",{"name":560,"class":46},"Isala",{"id":562,"slug":563,"hasResults":12,"nctId":564,"briefTitle":565,"officialTitle":566,"acronym":567,"eligibilityCriteria":568,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":569,"targetDuration":4,"studyType":22,"phases":571,"briefSummary":572,"conditions":573,"keywords":576,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":580,"lastUpdatePostDateStruct":581,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":587,"locationsCount":105},"100589853","impact-of-adapted-aesthetic-onco-in-patients-with-upper-aerodigestive-tract-cancer-during-their-management-100589853","NCT06959810","Impact of Adapted Aesthetic Onco in Patients With Upper Aerodigestive Tract Cancer During Their Management","Impact of Adapted Aesthetic Onco in Patients With Cancer of the Upper Aero-digestive Tract During Their Management [ŒUVRE (Adapted Aesthetic Onco Aero-digestive Tract)]","OEUVRE","Inclusion Criteria:\n\n* Patient aged 18 or over\n* Neoplastic location: oropharynx, oral cavity, hypopharynx, larynx, nasal cavity, salivary glands, cavum, sinus.\n* Patient due to start oncological treatment (recurrence authorized)\n* Patient fluent in French.\n* Affiliation with a social security scheme\n* Signature of informed consent prior to any specific procedure linked to the study\n* Treatment with curative intent\n\nExclusion Criteria:\n\n* Breast-feeding or pregnant patient\n* Any associated medical or psychological condition that could compromise the patient's ability to participate in the study\n* Patient deprived of liberty, under guardianship, or subject to a legal protection measure or unable to express their consent.\n* Patient unable to undergo trial follow-up for geographical, social or psychopathological reasons.",{"count":570,"type":21},55,[24],"Treatment for cancers of the pharyngolarynx is mutilating, with major consequences for patients' lives in terms of physical and functional after-effects. The psycho-social consequences are also significant, notably the metamorphosis of identity linked to the disease and its treatment, which alters the patient's self-image.\n\nInitial feedback from patients who have been able to benefit from adapted oncoesthetics (OEA) is overwhelmingly positive.\n\nThis study will assess the feasibility of oncoesthetics and describe any obstacles.",[27,574,575],"Aerodigestive Tract Cancer","Suportive Care",[577,578,579],"Oncology (Organ: Upper Aero Digestive Tract)","Supportive Oncology","Organization of care","2026-03-11",{"date":582,"type":39},"2026-03-12",{"date":584,"type":39},"2025-10-24",{"date":586,"type":21},"2028-09-15",{"name":588,"class":46},"Centre Francois Baclesse",{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":594,"acronym":595,"eligibilityCriteria":596,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":597,"targetDuration":598,"studyType":57,"phases":4,"briefSummary":599,"conditions":600,"keywords":608,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":617,"lastUpdatePostDateStruct":618,"startDateStruct":619,"completionDateStruct":621,"leadSponsor":623,"locationsCount":105},"100613134","developing-a-multimodal-cancer-pain-database-to-support-ai-based-automatic-pain-assessment-100613134","NCT07262632","Developing a Multimodal Cancer Pain Database to Support AI-Based Automatic Pain Assessment","SENSAI: Seeing, hEaring, seNsing: Smart, Effortless and Objective Pain Assessment With Mobile AI Technology - DataBase Development","SENSAI-DBD","Inclusion Criteria:\n\n* Adult patients (≥18 years)\n* Diagnosed with cancer, active\n* Able to communicate verbally in Dutch or English\n* Able to provide written informed consent.\n* Pain group specific:\n* Experiencing pain related to cancer\n* Admitted to the hospital due to pain\n* Control group specific:\n* Not experiencing pain (NRS = 0)\n* Admitted to the hospital for chemotherapy\n\nExclusion Criteria:\n\n* Cognitive, physical, or medical limitations that prevent participation in the audiovisual recording sessions or affect facial expressions or voice (e.g. facial paralysis, tracheostomy, severe speech impairment).\n* Critical illness or end-of-life care where participation would impose an additional burden.\n* Experiencing pain not associated with cancer\n* Infectious isolation precautions that prevent safe data collection",{"count":81,"type":21},"3 Weeks","The goal of this observational study is to collect short video and sound recordings of people with cancer to create a secure database that can be used in future research to develop an artificial intelligence (AI) tool for pain assessment. The main aim is to build a large, high-quality collection of audiovisual data showing how people with cancer express themselves when they do and do not have pain.\n\nParticipants will include adults with cancer who are admitted to the oncology ward for pain treatment and a control group admitted for chemotherapy who have no pain. After giving consent, participants will:\n\n* Be recorded on video (from the shoulders up) for up to 60 seconds while reading a short sentence and describing their pain or daily experience.\n* Complete a short questionnaire about their mood and pain expression.\n* Allow researchers to collect some information from their medical record, such as their pain score, medications, and cancer type.\n\nThese recordings will be securely stored and used to create a database for future AI research. No medical tests, new treatments, or extra hospital visits are involved. This study will provide the foundation for developing future AI-based tools that could support doctors and patients in monitoring and managing pain more accurately and easily.",[601,602,603,27,604,605,606,607,61],"Cancer-related Pain","Pain Assessment","Artificial Intelligence (AI)","Oncology Pain","Database","Facial Expression","Voice",[601,609,603,27,604,605,610,611,612,613,614,615,616],"Pain assessment","Facial Action Unit","Vocalizations","Acoustic","Automatic assessment","Machine learning","Audiovisual data","Paralinguistics","2026-03-10",{"date":580,"type":39},{"date":620,"type":39},"2025-12-01",{"date":622,"type":21},"2027-12-31",{"name":624,"class":46},"Dr. Mark Mulder",{"id":626,"slug":627,"hasResults":12,"nctId":628,"briefTitle":629,"officialTitle":630,"acronym":631,"eligibilityCriteria":632,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":633,"targetDuration":635,"studyType":57,"phases":4,"briefSummary":636,"conditions":637,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":674,"lastUpdatePostDateStruct":675,"startDateStruct":677,"completionDateStruct":679,"leadSponsor":681,"locationsCount":683},"100368284","the-momentum-study-the-multiple-outcome-evaluation-of-radiation-therapy-using-the-mr-linac-study-100368284","NCT04075305","The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study","The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study","MOMENTUM","Inclusion Criteria:\n\n* Patient is to undergo or has completed imaging or treatment procedures on an MR-Linac;\n* Patient provides written, informed consent;\n* Patient is 18 years old or older.\n\nExclusion Criteria:\n\n* MRI exclusion criteria, including\n* MRI contraindications as per usual clinical care, such as (possible) pregnancy; claustrophobia and metal or electronic implants not compatible with MRI.",{"count":634,"type":21},8000,"2 Years","The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.",[27,638,639,640,641,642,643,644,645,646,647,648,649,650,651,652,653,654,655,656,657,658,659,660,525,661,662,663,664,665,666,667,668,669,670,671,672,673],"Breast Cancer","Prostate Cancer","Gynecologic Cancer","Brain Tumor","Brain Cancer","Gynecologic Tumor","Prostate Tumor","Prostate Neoplasm","Breast Tumor","Radiation Toxicity","Quality of Life","Rectal Cancer","Rectal Tumor","Rectal Neoplasms","Lung Cancer","Lung Tumor","Lung Neoplasm","Esophageal Cancer","Esophagus Cancer","Esophageal Tumor","Esophageal Neoplasm","Esophagus Tumor","Esophagus Neoplasm","Pancreatic Tumor","Pancreatic Neoplasms","Head and Neck Cancer","Head and Neck Neoplasms","Head and Neck Tumor","Tumor","Neoplasms","Bladder Cancer","Bladder Neoplasm","Liver Cancer","Liver Neoplasms","Liver Metastases","Oligometastases","2026-03-03",{"date":676,"type":39},"2026-03-05",{"date":678,"type":39},"2019-02-01",{"date":680,"type":21},"2030-08-01",{"name":682,"class":46},"UMC Utrecht",18,{"id":685,"slug":686,"hasResults":12,"nctId":687,"briefTitle":688,"officialTitle":689,"acronym":690,"eligibilityCriteria":691,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":692,"targetDuration":694,"studyType":57,"phases":4,"briefSummary":695,"conditions":696,"keywords":699,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":704,"lastUpdatePostDateStruct":705,"startDateStruct":707,"completionDateStruct":709,"leadSponsor":711,"locationsCount":105},"100589104","curatively-intended-thoracic-reirradiation-100589104","NCT06950073","Curatively Intended Thoracic Reirradiation","CUratively Intended Thoracic REirradiation: An Observational Study of High-dose Reirradiation of Thoracic Tumours: A Multicentre Prospective Registration Protocol","CureLung","Inclusion Criteria:\n\n* Radiotherapy of thoracic lesion(s) (loco-regional lung cancer recurrence, new primary lung cancer, or solitary oligo metastasis) with the aim of long-term local control.\n* Reirradiation type 1 or type 2, i.e. previous radiotherapy to the thorax as per ESTRO-EORTC consensus definition of reirradiation \\[Andratschke 2022\\]. For the sake of this study, multiple treatments to the lungs will be classified as type 2 reirradiation.\n* Verification of malignancy based on biopsy. If no biopsy is available, the decision of reirradiation should be agreed upon in a multidisciplinary conference.\n* Available digital dose plan(s) from former radiotherapy course(s) (DICOM files) - note that multiple re-treatments are allowed.\n* Adequate lung function to tolerate treatment, at the discretion of the treating physician.\n* Ability to complete a radiotherapy course with the aim of local control.\n* ECOG Performance status 0-2.\n* Estimated life expectancy ≥ 6 months\n* Age ≥18 years\n* Signed informed consent\n\nExclusion Criteria:\n\n* Uncontrolled other malignancy.\n* The primary and the reirradiation treatment may not be quasi-simultaneous (i.e. the two treatments should be planned independently)\n* Pregnancy\n* Radiotherapy to a minimum CTV mean dose of 45 Gy for SCLC and 50 Gy for NSCLC and oligometastatic lesions. Treatment schedule according to local protocols and treating physician preference.",{"count":693,"type":21},500,"10 Years","The number of long-term lung cancer (LC) survivors increases, however many patients are diagnosed with recurrent or new thoracic cancers. High-dose reirradiation (reRT) is promising but associated with high severe toxicity rates. Existing studies are small lacking high-quality data, with no clear correlation between toxicity risk and delivered radiotherapy (RT) dose.\n\nThis Danish multicentre prospective cohort study aims to provide a framework for collecting radiotherapy-related toxicity data, loco-regional control, and overall survival data for patients with thoracic cancer undergoing reirradiation; with the ultimate aim of providing safe reirradiation to more patients.\n\nAs a secondary aim, guidelines for dose accumulation and provisional constraints for the organs at risk will be used to establish a uniform treatment strategy for reirradiation.\n\nThe CURE Lung trial will provide high-impact, globally missing data. This project will ensure full utilization of and learning from the trial, adding SDM, PROMs, and modality referral to the trial. It will model the correlation between toxicity burden and doses, enabling individualized reRT with optimized dose prescription based on toxicity risk and patient preferences, and assisting in the decision-making on the prescription dose and optimal modality. This will ensure safe reRT for the increasing number of long-term LC survivors.",[697,647,27,652,698],"Radiotherapy Side Effect","Thoracic Cancer",[700,701,702,703,652,27,647],"Reirradiation","Aarhus","Denmark","Thoracic cancer","2026-03-02",{"date":706,"type":39},"2026-03-04",{"date":708,"type":39},"2025-10-10",{"date":710,"type":21},"2035-05-01",{"name":712,"class":46},"University of Aarhus",{"id":714,"slug":715,"hasResults":12,"nctId":716,"briefTitle":717,"officialTitle":718,"acronym":719,"eligibilityCriteria":720,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":721,"targetDuration":4,"studyType":22,"phases":723,"briefSummary":724,"conditions":725,"keywords":726,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":729,"lastUpdatePostDateStruct":730,"startDateStruct":732,"completionDateStruct":734,"leadSponsor":736,"locationsCount":105},"100626720","monitoring-of-neurological-symptoms-treatment-tolerance-and-quality-of-life-using-the-resilience-pro-electronic-patient-reported-outcome-application-in-patients-with-idh-mutated-glioma-100626720","NCT07439302","Monitoring of Neurological Symptoms, Treatment Tolerance, and Quality of Life Using the Resilience PRO Electronic Patient-reported Outcome Application in Patients With IDH-mutated Glioma","A Prospective Multi-center Study to Monitor Neurological Symptoms, Treatment Tolerance, and Quality of Life Using the Resilience PRO Electronic Patient-reported Outcome Application in Patients With IDH-mutated Glioma","NEURO-PRO-GLIO","Inclusion Criteria:\n\n1. Adults (over 18 years of age)\n2. Written consent from the patient to participate in the clinical study\n3. Diagnosed with grade 2-4 glioma with IDH1\u002F2 mutation\n4. Plan to initiate new systemic treatment for glioma (chemotherapy, targeted therapy, or other investigational antitumor systemic agent)\n5. Candidate for ePRO monitoring using Resilience PRO medical device according to local investigator decision\n6. Social security coverage\n\nExclusion Criteria:\n\n1. Severe language impairment\n2. Cognitive deficit preventing the understanding of essential elements for questionnaires\n3. Patient under guardianship or curatorship",{"count":722,"type":21},80,[24],"Patients with IDH-mutant glioma frequently experience symptoms such as fatigue, seizures, headaches, cognitive impairments (primarily attentional), and mood changes, which can significantly affect their health-related quality of life (HRQoL). Disease progression and treatment-related toxicities are the two primary factors driving the decline in HRQoL in this population. These symptoms can be exacerbated by side effects from available therapeutic options, such as chemotherapy, radiation therapy, or targeted IDH inhibitors. In this context, it is crucial to consider the combined effects of these treatments on patient symptoms and HRQoL. Given that this population is young and otherwise healthy, with long-term survival exceeding 10 years after diagnosis, it is essential to consider not only on longevity but also on overall functioning and HRQoL when making treatment decisions. Assessing quality of life has therefore become a key parameter in phase III clinical trials and observational studies under real-world conditions.\n\nThe Resilience PRO digital medical device (DMD; CE-marked class IIa) enables remote monitoring of patients treated for cancer who are receiving systemic therapy. Resilience PRO has been positively evaluated by the French National Health Authority (HAS) and included on the LATM list under its brand name. Resilience PRO sends validated weekly questionnaires to patients (NCI PRO-CTCAE ePatient Reported Outcomes \\[ePROs\\]), inquiring about treatment- and disease-related symptomatic adverse events. The associated alert algorithm, equivalent to those used in the STAR and PRO-TECT studies, allows for the proactive management of severe or worsening symptoms by the healthcare professional receiving the alert. Additionally, Resilience PRO provides patients with personalized access to a mobile app that offers resources aimed at improving education, self-management, and patient engagement. These innovations lead to clinical benefits (improved quality of life, reduced morbidity, and increased overall survival), as well as organizational benefits (reduced emergency room visits and hospitalizations) and economic advantages.",[27,413],[148,413,727,728],"quality of life","Resilience Pro application","2026-02-23",{"date":731,"type":39},"2026-02-27",{"date":733,"type":21},"2026-09",{"date":735,"type":21},"2029-09",{"name":737,"class":46},"Assistance Publique - Hôpitaux de Paris"]